Hence, to promote CD95L-induced cell death over non-apoptotic cellular outcomes, it will also be required to define tumour contexts in which additional cell death checkpoints (e.g., mediated by IAPs) should be alleviated in concert with IRE1 inhibition. This evidence concerns the gene FASLG and neoplasm.